Pathstone Family Office’s NextCure NXTC Stock Holding History

Pathstone Family Office’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-17	Closed	-$2K	–	1284
2020 Q3	$2K	Buy	+17	New	+$2.09K	﹤0.01%	707

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Pathstone Family Office's NXTC Position: Q4 2020 in Review

Pathstone Family Office sold out of NextCure (NXTC) in Q4 2020, closing a stake of 17 shares — an estimated $2K sold.

Pathstone Family Office first reported a position in NXTC in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 83 funds tracked by Wall St. Rank hold NXTC as of Q4 2020.

Pathstone Family Office reported no remaining NextCure position as of Q4 2020 after selling out during the quarter.
Pathstone Family Office sold 17 NextCure shares in Q4 2020, an estimated $2K.
Pathstone Family Office first reported a position in NextCure in Q3 2020 and held it in 1 quarter.
Pathstone Family Office's NextCure position peaked at $2K in Q3 2020.
83 funds tracked by Wall St. Rank held NextCure as of Q4 2020.

Based on Pathstone Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.